Global HARMONi data show ivonescimab plus chemotherapy reduced progression or death risk by 48% after third-generation EGFR-TKI failure, while overall survival had not reached statistical significance at the primary analysis.
Zipalertinib’s pivotal REZILIENT3 data will debut at WCLC 2026 after the first-line lung cancer trial met its PFS endpoint.
Obsidian Therapeutics closes its Galera merger and $350 million financing, putting OBX-115 melanoma data and execution under investor scrutiny.
Akeso has started a Phase Ib/II lung cancer trial of HER3 ADC AK138D1 with ivonescimab. See what the combination must prove.
Verastem begins TARGET-D 202, testing 900 mg VS-7375 in previously treated KRAS G12D NSCLC, including a brain metastases cohort.
Natera’s Signatera gains European IVDR certification across multiple cancers, opening a new phase for personalized MRD testing and clinical adoption.
MAIA Biotechnology has reported positive initial efficacy data from Part C of the Phase 2 THIO-101 expansion trial evaluating ateganosine followed by cemiplimab in third-line advanced non-small cell lung cancer. The clinical-stage oncology drug developer said the regimen produced a 90.5 percent interim disease control rate among efficacy-evaluable patients, placing its telomere-targeting strategy back in
Discover why Abbisko and AstraZeneca are testing oral PD-L1 inhibitor lumipodlin with Tagrisso in EGFR-mutated lung cancer.
Read how Samsung Bioepis SB27’s positive Phase 1 and Phase 3 data could reshape the Keytruda biosimilar race and oncology access.
Discover why Pfizer’s sigvotatug vedotin Phase 3 miss shifts attention to second-line patients, biomarkers and first-line combinations.